Cargando…

Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development

Background: A critical step in tuberculosis (TB) drug development is the Phase 2a early bactericidal activity (EBA) study which informs if a new drug or treatment has short-term activity in humans. The aim of this work was to present a standardized pharmacometric model-based early bactericidal activ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mockeliunas, Laurynas, Faraj, Alan, van Wijk, Rob C., Upton, Caryn M., van den Hoogen, Gerben, Diacon, Andreas H., Simonsson, Ulrika S. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133723/ https://www.ncbi.nlm.nih.gov/pubmed/37124198 http://dx.doi.org/10.3389/fphar.2023.1150243

Ejemplares similares

Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19
por: van Wijk, Rob C., et al.
Publicado: (2023)

Seasonal influence on respiratory tract infection severity including COVID‐19 quantified through Markov Chain modeling
por: van Wijk, Rob C., et al.
Publicado: (2023)

Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial
por: Upton, Caryn M., et al.
Publicado: (2022)

Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients
por: Faraj, Alan, et al.
Publicado: (2020)

Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development
por: Ayoun Alsoud, Rami, et al.
Publicado: (2023)

Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of in vitro, in vivo methodologies and human studies
por: Alffenaar, Jan-Willem C., et al.
Publicado: (2022)

Derivation and Clinical Utility of Safety Targets for Linezolid-Related Adverse Events in Drug-Resistant Tuberculosis Treatment
por: Keutzer, Lina, et al.
Publicado: (2023)

Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis
por: Mockeliunas, Laurynas, et al.
Publicado: (2022)

Finding the right hazard function for time‐to‐event modeling: A tutorial and Shiny application
por: Van Wijk, Rob C., et al.
Publicado: (2022)

Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing—Using Rifampicin as an Example
por: Keutzer, Lina, et al.
Publicado: (2020)

Model‐informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy
por: Faraj, Alan, et al.
Publicado: (2023)

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis
por: Stemkens, Ralf, et al.
Publicado: (2023)

Anti‐tuberculosis effect of isoniazid scales accurately from zebrafish to humans
por: van Wijk, Rob C., et al.
Publicado: (2020)

The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis
por: Abulfathi, Ahmed A., et al.
Publicado: (2021)

A model-based analysis identifies differences in phenotypic resistance between in vitro and in vivo: implications for translational medicine within tuberculosis
por: Clewe, Oskar, et al.
Publicado: (2020)

Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis
por: Diacon, Andreas H., et al.
Publicado: (2020)

Bactericidal Activity of Lipid-Shelled Nitric Oxide-Loaded Microbubbles
por: Lafond, Maxime, et al.
Publicado: (2020)

Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictions
por: Faraj, Alan, et al.
Publicado: (2020)

A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses
por: Svensson, Robin J., et al.
Publicado: (2017)

Combinations of β-Lactam Antibiotics Currently in Clinical Trials Are Efficacious in a DHP-I-Deficient Mouse Model of Tuberculosis Infection
por: Rullas, Joaquín, et al.
Publicado: (2015)

Targeting IgG Autoantibodies for Improved Cytotoxicity of Bactericidal Permeability Increasing Protein in Cystic Fibrosis
por: McQuillan, Karen, et al.
Publicado: (2020)

Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data
por: Mudde, Saskia E, et al.
Publicado: (2021)

Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg(−1) rifampicin
por: te Brake, Lindsey H.M., et al.
Publicado: (2021)

Quantification of Natural Growth of Two Strains of Mycobacterium Marinum for Translational Antituberculosis Drug Development
por: Van Wijk, Rob C., et al.
Publicado: (2020)

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline
por: Tanneau, Lénaïg, et al.
Publicado: (2022)

Mobile Health Apps for Improvement of Tuberculosis Treatment: Descriptive Review
por: Keutzer, Lina, et al.
Publicado: (2020)

8‐Hydroxyquinolines are bactericidal against Mycobacterium tuberculosis
por: Odingo, Joshua O., et al.
Publicado: (2019)

Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug
por: Faraj, Alan, et al.
Publicado: (2022)

Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country
por: Wahid, Abdul, et al.
Publicado: (2022)

Evaluation of optimized bronchoalveolar lavage sampling designs for characterization of pulmonary drug distribution
por: Clewe, Oskar, et al.
Publicado: (2015)

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis
por: Svensson, Elin M, et al.
Publicado: (2018)

Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients
por: Faraj, Alan, et al.
Publicado: (2023)

Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832
por: Dawson, Rodney, et al.
Publicado: (2023)

Large Sample Size Fallacy in Trials About Antipsychotics for Neuropsychiatric Symptoms in Dementia
por: Hulshof, Tessa A., et al.
Publicado: (2020)

A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro
por: Clewe, Oskar, et al.
Publicado: (2016)

Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting Dose
por: Andrews, Louise M., et al.
Publicado: (2017)

Plakinamine P, A Steroidal Alkaloid with Bactericidal Activity against Mycobacterium tuberculosis
por: Rodrigues Felix, Carolina, et al.
Publicado: (2019)

Clinical pharmacy services for tuberculosis management: a systematic review
por: Iskandar, D., et al.
Publicado: (2023)

Effects of Nanopillar Size and Spacing on Mechanical Perturbation and Bactericidal Killing Efficiency
por: Velic, Amar, et al.
Publicado: (2021)

Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism
por: Koul, Anil, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_o0001qoth0u0s2tbs4h65c6v7q